Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 7/20 | 0.74 |
| ▸ | MAPK12 | P53778 | 7/20 | 0.74 |
| ▸ | MAPK11 | Q15759 | 7/20 | 0.74 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.74 |
| ▸ | GCGR | P47871 | 5/20 | 0.74 |
| ▸ | MAPT | P10636 | 4/20 | 0.65 |
| ▸ | TP53 | P04637 | 3/20 | 0.65 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | RAF1 | P04049 | 2/20 | 0.51 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.50 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.49 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6468983 | 0.86 | MAPT (0.63) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL6470581 | 0.85 | MAPK13 (0.81) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL11176392 | 0.85 | MAPK13 (1.00) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL28158811 | 0.85 | MAPK13 (0.86) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL6469901 | 0.84 | MAPK14 (0.78) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL2649482 | 0.84 | MAPK14 (1.00) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL6449249 | 0.83 | MAPK14 (0.64) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL6469131 | 0.81 | MMP13 (0.65) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL6470570 | 0.81 | MAPK14 (0.74) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL14514175 | 0.80 | PTPN1 (0.73) | MAPK13MAPK12MAPK11MAPK14GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050203155-A1 | Imidazole compounds and human cellular proteins casein kinase I alpha, delta and epsilon as targets for medical intervention against Hepatitis C Virus infections | AXXIMA PHARMACEUTICAL AG. (DE) | 2005-09-15 | — | — | US | claimed |
| EP-1532118-A2 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | Axxima Pharmaceuticals Aktiengesellschaft (DE) | 2005-05-25 | — | — | EP | claimed |
| WO-2004005264-A2 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | AXXIMA PHARMACEUTICALS AG (DE) | 2004-01-15 | — | — | WO | claimed |
| US-20240000821-A1 | CHEMICAL INHIBITORS AGAINST KINASES TO BLOCK TELOMERE ELONGATION IN CANCER | UNIV JOHNS HOPKINS (US) | 2024-01-04 | — | — | US | disclosed |
| US-20200078387-A1 | CHEMICAL INHIBITORS AGAINST KINASES TO BLOCK TELOMERE ELONGATION IN CANCER | THE JOHNS HOPKINS UNIVERSITY | 2020-03-12 | — | — | US | disclosed |
| WO-2018112342-A1 | CHEMICAL INHIBITORS AGAINST KINASES TO BLOCK TELOMERE ELONGATION IN CANCER | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-06-21 | — | — | WO | disclosed |
| US-20050203155-A1 | Imidazole compounds and human cellular proteins casein kinase I alpha, delta and epsilon as targets for medical intervention against Hepatitis C Virus infections | AXXIMA PHARMACEUTICAL AG. (DE) | 2005-09-15 | — | — | US | disclosed |
| EP-1532118-A2 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | Axxima Pharmaceuticals Aktiengesellschaft (DE) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004005264-A2 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | AXXIMA PHARMACEUTICALS AG (DE) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203155-A1 | Imidazole compounds and human cellular proteins casein kinase I alpha, delta and epsilon as targets for medical intervention against Hepatitis C Virus infections | CSNK1G1, CSNK1E, CSNK1D | MAPK13 456/4885MAPK12 732/4885MAPK11 1215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.